[
  {
    "ts": null,
    "headline": "Amgen (AMGN) Dips More Than Broader Market: What You Should Know",
    "summary": "Amgen (AMGN) closed at $279.22 in the latest trading session, marking a -2.65% move from the prior day.",
    "url": "https://finnhub.io/api/news?id=e06b66d02197583a3808db237061f11e9670d649a6eb12126b97b200a0903ab9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758750603,
      "headline": "Amgen (AMGN) Dips More Than Broader Market: What You Should Know",
      "id": 136879428,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (AMGN) closed at $279.22 in the latest trading session, marking a -2.65% move from the prior day.",
      "url": "https://finnhub.io/api/news?id=e06b66d02197583a3808db237061f11e9670d649a6eb12126b97b200a0903ab9"
    }
  },
  {
    "ts": null,
    "headline": "Takeda: Excellent Pipeline Kaizen - 6 Drugs, $20 Billion Annually",
    "summary": "Takeda offers a compelling investment case with six late-stage therapies targeting $20 billion in peak sales by 2030-31. Click to read why TAK is a Strong Buy.",
    "url": "https://finnhub.io/api/news?id=7ecb21fb8423fde87617c6680b90e9f8522d8dbd7307e733cd3cdfce246117e3",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758735634,
      "headline": "Takeda: Excellent Pipeline Kaizen - 6 Drugs, $20 Billion Annually",
      "id": 136865405,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1162606801/image_1162606801.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Takeda offers a compelling investment case with six late-stage therapies targeting $20 billion in peak sales by 2030-31. Click to read why TAK is a Strong Buy.",
      "url": "https://finnhub.io/api/news?id=7ecb21fb8423fde87617c6680b90e9f8522d8dbd7307e733cd3cdfce246117e3"
    }
  },
  {
    "ts": null,
    "headline": "Dow's 119-point drop led by losses in Amgen, Apple shares",
    "summary": "Dow's 119-point drop led by losses in Amgen, Apple shares",
    "url": "https://finnhub.io/api/news?id=f3aef31ecaf9221d1dec33688a42c3576738c06f5ae52d9d1fda5d29e742f922",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758714720,
      "headline": "Dow's 119-point drop led by losses in Amgen, Apple shares",
      "id": 136868039,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "Dow's 119-point drop led by losses in Amgen, Apple shares",
      "url": "https://finnhub.io/api/news?id=f3aef31ecaf9221d1dec33688a42c3576738c06f5ae52d9d1fda5d29e742f922"
    }
  },
  {
    "ts": null,
    "headline": "Amgen: Imdelltra Could Be The Next Game Changer",
    "summary": "Amgen: Imdelltra Could Be The Next Game Changer",
    "url": "https://finnhub.io/api/news?id=a15d953742da50b01f3453fd76eb35d73a9e11cbcaa6e56e032929c5a6813b78",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758709050,
      "headline": "Amgen: Imdelltra Could Be The Next Game Changer",
      "id": 136861111,
      "image": "",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=a15d953742da50b01f3453fd76eb35d73a9e11cbcaa6e56e032929c5a6813b78"
    }
  },
  {
    "ts": null,
    "headline": "Pharma’s next generation of blockbuster antibodies takes a ‘more is better’ approach",
    "summary": "Why multi-specific antibodies are seeing a fresh surge of industry buzz.",
    "url": "https://finnhub.io/api/news?id=f36d59b789ed4497588450b6fc06c748913d886c801448d7fc0c0d9fb864260d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758700800,
      "headline": "Pharma’s next generation of blockbuster antibodies takes a ‘more is better’ approach",
      "id": 136861770,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Why multi-specific antibodies are seeing a fresh surge of industry buzz.",
      "url": "https://finnhub.io/api/news?id=f36d59b789ed4497588450b6fc06c748913d886c801448d7fc0c0d9fb864260d"
    }
  },
  {
    "ts": null,
    "headline": "A Once-in-a-Decade Opportunity: 10 Billion Reasons to Pay Attention to This Monster Quantum Computing Company (Hint: Not IonQ)",
    "summary": "A new quantum computing start-up called Quantinuum was just valued at $10 billion.",
    "url": "https://finnhub.io/api/news?id=cfe830f56b2e8c486f9de0f3fb4d4eec50d6a6dae96b8995b12578ac8ed8ec35",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758697200,
      "headline": "A Once-in-a-Decade Opportunity: 10 Billion Reasons to Pay Attention to This Monster Quantum Computing Company (Hint: Not IonQ)",
      "id": 136861495,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "A new quantum computing start-up called Quantinuum was just valued at $10 billion.",
      "url": "https://finnhub.io/api/news?id=cfe830f56b2e8c486f9de0f3fb4d4eec50d6a6dae96b8995b12578ac8ed8ec35"
    }
  }
]